Day: October 13, 2023

THIS PRESS RELEASE IS NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO, OR TO ANY PERSON LOCATED OR RESIDENT IN AUSTRALIA, CANADA, JAPAN, OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. Amsterdam, 13 October 2023 EXOR ANNOUNCES OVERSUBSCRIBED TENDER OFFER, PART OF ITS €1 BILLION SHARE BUYBACK PROGRAM Exor N.V. (“Exor” or the “Company”) announces the results of the Tender Offer set out in the Offer Memorandum published by the Company on 13 September 2023 (the “Offer Memorandum”). The Tender Offer closed at 17:40 CET on 12 October 2023. 25,424,248 Ordinary Shares were validly tendered by Qualifying Shareholders in the Tender Offer and, following application of the scaling-down mechanism set out in the Offer Memorandum, 8,873,452 Ordinary Shares will be purchased...

Tryg will host a Capital markets day for investors, analysts, and other financial markets participants on 4 December 2024 in London. The event will focus on 2027 financial targets and long-term strategy. Additional details, including registration for participation, will be distributed closer to the date of the events.AttachmentTryg Capital markets day 2024 Announcement

  Today, Tryg A/S (“Tryg”) announces that the Board of Directors has decided to initiate a share buyback programme of up to DKK 1.0 billion. The share buyback programme is launched with reference to the authorisation to acquire treasury shares granted by the general meeting on 30 March 2023. The authorisation is valid until 31 December 2024 and allows Tryg to acquire shares with a total nominal value of up to DKK 317,417,490 corresponding to app. 10 % of its share capital. The share buyback programme will start on 16 October 2023 and end no later than 31 January 2024. The share buyback programme will be executed in accordance with EU Market Abuse Regulation, EU Regulation no. 596/2014 of 16 April 2014 and the provisions of Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Regulation”). Johan Kirstein Brammer,...

   WISeKey’s Subsidiary, WISe.ART Launches a Marketing Campaign Aiming to Enlist Galleries, Museums, and Artists on its MarketPlace Calling All Artists: Dive into the Future of Art with WISe.ART! Geneva – October 13, 2023 – WISeKey International Holding Ltd. (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a global leader in cybersecurity, digital identity, and Internet of Things (IoT) solutions operating as a holding company, today announced that is subsidiary WISe.ART is launching a marketing campaign aiming to enlist galleries, museums, and artists on its NFT MarketPlace. Interested parties can join the platform vis WISe.ART. How it worksThe platform offers all artists and curators/agents the ability to join and submit applications. Onboarding is free. WISe.ART vetting committee to evaluate each submission and connect with each artist...

Ad hoc announcement pursuant to Art. 53 LRCommittee for Medicinal Products for Human Use (CHMP) issues positive opinion for AGAMREE® (vamorolone) for the treatment Duchenne muscular dystrophy (DMD) in children and adults aged 4 years and older European Commission (EC) decision on marketing authorization is expected in late 2023 AGAMREE could become the first drug fully approved by the European Medicines Agency (EMA) for the treatment of patients with DMD Anticipation of vamorolone approval in the U.S. on the PDUFA date of October 26, 2023Pratteln, Switzerland, October 13, 2023 – Santhera Pharmaceuticals (SIX: SANN) announces that the CHMP adopted a positive opinion in favor of approval of AGAMREE® (vamorolone) for the treatment of DMD patients aged 4 years and older. In its recommendation for approval, the CHMP acknowledges the positive...

CUNY’s report makes no findings of data manipulation. The “egregious misconduct” cited in the report relates to internal record-keeping failures at CUNY. CUNY’s report finds that internal record-keeping failures “prevented us [CUNY] from making an objective assessment” of research misconduct. Leak of CUNY report preceded by massive increase in short selling.AUSTIN, Texas, Oct. 12, 2023 (GLOBE NEWSWIRE) — Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today issued the following statement regarding an internal report purportedly prepared by City University of New York (CUNY). This report was leaked to the press. The leak of the CUNY report was preceded by a 40% increase in short selling activity in the stock of Cassava Sciences. Beginning August 2021, short sellers...